Chaytow H - Search Results

1

Targeting common disease pathomechanisms to treat amyotrophic lateral sclerosis.

Faller KME, Chaytow H, Gillingwater TH. Faller KME, et al. Among authors: chaytow h. Nat Rev Neurol. 2025 Jan 2. doi: 10.1038/s41582-024-01049-4. Online ahead of print. Nat Rev Neurol. 2025. PMID: 39743546 Review.

2

Author Correction: AI is a viable alternative to high throughput screening: a 318-target study.

Atomwise AIMS Program. Atomwise AIMS Program. Sci Rep. 2024 Sep 16;14(1):21579. doi: 10.1038/s41598-024-70321-w. Sci Rep. 2024. PMID: 39284864 Free PMC article. No abstract available.

3

Timing of SMN replacement therapies in mouse models of spinal muscular atrophy: a systematic review and meta-analysis.

Chaytow H, Motyl AAL, Huang YT, Wong C, Currie GL, Bahor Z, Sena E, Gillingwater TH. Chaytow H, et al. Brain Commun. 2024 Aug 12;6(4):fcae267. doi: 10.1093/braincomms/fcae267. eCollection 2024. Brain Commun. 2024. PMID: 39185027 Free PMC article.

4

AI is a viable alternative to high throughput screening: a 318-target study.

Atomwise AIMS Program. Atomwise AIMS Program. Sci Rep. 2024 Apr 2;14(1):7526. doi: 10.1038/s41598-024-54655-z. Sci Rep. 2024. PMID: 38565852 Free PMC article.

5

Excitotoxicity and ALS: New therapy targets an old mechanism.

Smith HL, Chaytow H, Gillingwater TH. Smith HL, et al. Among authors: chaytow h. Cell Rep Med. 2024 Feb 20;5(2):101423. doi: 10.1016/j.xcrm.2024.101423. Cell Rep Med. 2024. PMID: 38382464 Free PMC article.

6

Long-term muscle-specific overexpression of DOK7 in mice using AAV9-tMCK-DOK7.

Huang YT, Crick HR, Chaytow H, van der Hoorn D, Alhindi A, Jones RA, Hector RD, Cobb SR, Gillingwater TH. Huang YT, et al. Among authors: chaytow h. Mol Ther Nucleic Acids. 2023 Aug 2;33:617-628. doi: 10.1016/j.omtn.2023.07.036. eCollection 2023 Sep 12. Mol Ther Nucleic Acids. 2023. PMID: 37637210 Free PMC article.

7

Neuromuscular junction denervation and terminal Schwann cell loss in the hTDP-43 overexpression mouse model of amyotrophic lateral sclerosis.

Alhindi A, Shand M, Smith HL, Leite AS, Huang YT, van der Hoorn D, Ridgway Z, Faller KME, Jones RA, Gillingwater TH, Chaytow H. Alhindi A, et al. Among authors: chaytow h. Neuropathol Appl Neurobiol. 2023 Aug;49(4):e12925. doi: 10.1111/nan.12925. Neuropathol Appl Neurobiol. 2023. PMID: 37465879

8

Targeting phosphoglycerate kinase 1 with terazosin improves motor neuron phenotypes in multiple models of amyotrophic lateral sclerosis.

Chaytow H, Carroll E, Gordon D, Huang YT, van der Hoorn D, Smith HL, Becker T, Becker CG, Faller KME, Talbot K, Gillingwater TH. Chaytow H, et al. EBioMedicine. 2022 Sep;83:104202. doi: 10.1016/j.ebiom.2022.104202. Epub 2022 Aug 11. EBioMedicine. 2022. PMID: 35963713 Free PMC article.

9

The mitochondrial protein Sideroflexin 3 (SFXN3) influences neurodegeneration pathways in vivo.

Ledahawsky LM, Terzenidou ME, Edwards R, Kline RA, Graham LC, Eaton SL, van der Hoorn D, Chaytow H, Huang YT, Groen EJN, Motyl AAL, Lamont DJ, Tokatlidis K, Wishart TM, Gillingwater TH. Ledahawsky LM, et al. Among authors: chaytow h. FEBS J. 2022 Jul;289(13):3894-3914. doi: 10.1111/febs.16377. Epub 2022 Feb 6. FEBS J. 2022. PMID: 35092170 Free PMC article.

10

A new strategy to increase RNA editing at the Q/R site of GluA2 AMPA receptor subunits by targeting alternative splicing patterns of ADAR2.

Chaytow H, Sethw Hassan I, Akbar S, Popplewell L, Dickson G, Chen PE. Chaytow H, et al. J Neurosci Methods. 2021 Dec 1;364:109357. doi: 10.1016/j.jneumeth.2021.109357. Epub 2021 Sep 16. J Neurosci Methods. 2021. PMID: 34536489 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters